STRO

Sutro Biopharma Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 3/10
Sutro Biopharma sales and earnings growth
STRO Growth
Neutral
  • Revenue Y/Y↓ -34.36%
  • EPS Y/Y↓ -62.11%
  • FCF Y/Y↓ -106.15%
Sutro Biopharma gross and profit margin trends
STRO Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -205.20%
  • ROIC 5Y↓ -75.24%
Sutro Biopharma net debt vs free cash flow
STRO Risk
Great
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -303.2

Sutro Biopharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗